To address these diagnostic gaps, URO17® has emerged as a noninvasive, urine-based immunocytochemistry assay that detects Keratin 17 (K17), a biomarker overexpressed in urothelial carcinoma cells. The gene discussed is KRT17; the disease is urothelial carcinoma.